Abstract:Abstract Background lncRNA-CDKN2B antisense RNA 1 (ANRIL) and SRY-box transcription factor 9 (SOX9) has abnormal expression in many tumors including glioma, but the underlying molecular mechanism is unclear. This study set out to investigate the serum lncRNA-ANRIL and SOX9 levels in glioma patients and their effects on prognosis. Methods We enrolled 142 glioma patients admitted to our hospital from May 2014 to May 2016 into the research group (RG) and 120 healthy subjects receiving concurrent physical examinations into the control group (CG). Fasting peripheral blood (4 mL each) wa s sampled from subjects from the two groups. Using the quantitative real-time polymerase chain reaction (qRT-PCR), lncRNA-ANRIL and SOX9 were measured to explore their values in the early diagnosis of glioma. Patients from RG were followed up for 3 years to analyze the influence of lncRNA-ANRIL and SOX9 on patient prognosis. We purchased glioma cell lines U251 and U87 and grouped them according to the transfection of different plasmids. We conducted CCK8 assay to test cell proliferation, Transwell assay to test cell invasion, the flow cytometry to test cell apoptosis, and Western Blot assay to measure bcl-2 and bax protein levels. Results ANRIL and SOX9 were evidently higher in RG than in CG ( P <0.01). The receiver operating characteristic (ROC) curve revealed that the diagnostic sensitivity of ANRIL combined with SOX9 for glioma was 81.62%, and the specificity was 90.83% ( P <0.01). ANRIL and SOX9 were closely related to tumor grade, tumor diameter, distant metastasis, and family history of glioma ( P <0.01). In total, 135 patients were successfully followed up (95.07%). Patients with high levels of ANRIL and SOX9 had a markedly poorer prognosis than those with low levels ( P <0.05). ANRIL and SOX9 were markedly higher in glioma cell lines (U251 and U87) than in normal brain cells ( P <0.01). The proliferation and invasion of U251 cells were notably reduced after the transfection of ANRIL and SOX9 inhibitory sequences ( P <0.01), but the apoptosis was notably increased ( P <0.01). Bcl-2 expression was markedly increased in lncRNA-ANRIL-inhibitor and SOX9-inhibitor ( P <0.01), while bax expression was markedly reduced in lncRNA-ANRIL-inhibitor and SOX9-inhibitor ( P <0.01). Conclusion lncRNA-ANRIL and SOX9 levels were higher in glioma patients than in healthy people. High-lncRNA-ANRIL and SOX9 levels were strongly associated with unfavorable prognosis of patients. The testing of biological behaviors revealed that lncRNA-ANRIL and SOX9 worked as tumor-promoting genes in glioma.

Loss of heterozygosity of chromosome 1p/19q and p53 protein expression in oligodendroglioma

Quantitative Proteomic Analysis of Oligodendrogliomas with and Without 1p/19q Deletion

Chromosome 1p/19q status combined with expression of p53 protein improves the diagnostic and prognostic evaluation of oligodendrogliomas.

Itraq-Based Quantitative Proteomic Analysis for Identification of Oligodendroglioma Biomarkers Related with Loss of Heterozygosity on Chromosomal Arm 1P

Not All 1p/19q Non-Codeleted Oligodendroglial Tumors Are Astrocytic

Detection of chromosomal imbalance in oligodendroglial tumors by comparative genomic hybridization

Detection of Loss of Heterozygosity on Chromosome 1p in Oligodendrogliomas by Fluorescence in Situ Hybridization

Loss of OPCML Expression and the Correlation with CpG Island Methylation and LOH in Ovarian Serous Carcinoma.

Surgically Treated Incidentally Discovered Low-Grade Gliomas Are Mostly Idh Mutated And 1p19q Co-Deleted With Favorable Prognosis

Loss of Cic and Fubp1 Expressions Are Potential Markers of Shorter Time to Recurrence in Oligodendroglial Tumors

Diagnostic accuracy of 1p/19q codeletion tests in oligodendroglioma: A comprehensive meta‐analysis based on a Cochrane systematic review

Glioma SOX2 Expression Decreased after Adjuvant Therapy.

Differential Expression of P42.3 in Low- and High-Grade Gliomas

Biom-30. Novel Histologic And Molecular Biomarkers For Oligodendroglioma

Prognostic factors for patients with glioma located in brain eloquent areas

Study of Loss of Heterozygosity on Chromosome 9p21-22 in Sporadic Gliomas

Path-32. The Prognostic Impact Of Cdkn2A/B Heterozygous Deletions In Idh-Mutant Glioma

Allelic loss is heterogeneous throughout the tumor in colorectal carcinoma

Serum lncRNA-ANRIL and SOX9 expression levels in glioma patients and their relationship with poor prognosis

Determination of genetic aberrations and novel transcripts involved in the pathogenesis of oligodendroglioma using array comparative genomic hybridization and next generation sequencing

Expressions of transforming growth factor-β 1 and p53 proteins in diffuse glioma and their significances